Upgrade to SI Premium - Free Trial

Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag'

March 25, 2026 10:33 AM
Leerink Partners analyst Joseph P. Schwartz reiterated a Market Perform rating and $15.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles